Asthma and Cushing's syndrome

被引：26

作者：

Wilson, AM

Blumsohn, A

Jung, RT

Lipworth, BJ ^{[1
]}

机构：

[1] Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland

[2] Univ Dundee, Ninewells Hosp & Med Sch, Dept Biochem Med, Dundee DD1 9SY, Scotland

[3] Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland

来源：

CHEST | 2000年 / 117卷 / 02期

关键词：

adrenal suppression; Cushing's syndrome; fluticasone propionate; osteoporosis;

D O I：

10.1378/chest.117.2.593

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A female patient was treated with high-dose inhaled fluticasone propionate for her asthma, Over 2 years, she developed features of Cushing's syndrome with proximal myopathy, osteopenia, hypertension, depressive psychosis, and cushingoid appearance. She had biochemical evidence of marked adrenal suppression with a 9:00 AM serum cortisol of 20 nmol/L that returned to normal (315 mol/L) after her therapy was changed to budenoside, 0.8 mg/d, Her appearance, mental state, and myopathy also improved with no loss of asthma control. This case illustrates the potential for developing clinically relevant adverse effects of inhaled corticosteroids when given at licensed doses.

引用

页码：593 / 594

页数：2

共 6 条

[1] Hypothalamic-pituitary-adrenal axis suppression associated with the use of inhaled fluticasone propionate [J].